A B S T R A C T Experimental diabetes consistently reduces the concentration of free myo-inositol in peripheral nerve, which usually exceeds that of plasma by 90-100-fold. This phenomenon has been explicitly linked to the impairment of nerve conduction in the acutely diabetic streptozocin-treated rat. However, the mechanism by which acute experimental diabetes lowers nerve myo-inositol content and presumably alters nerve myo-inositol metabolism is unknown. Therefore, the effects of insulin and elevated medium glucose concentration on 2-[3H]myo-inositol uptake were studied in a metabolically-defined in vitro peripheral nerve tissue preparation derived from rabbit sciatic nerve, whose free myo-inositol content is reduced by experimental diabetes. The results demonstrate that myo-inositol uptake occurs by at least two distinct transport systems in the normal endoneurial preparation. A sodium-and energy-dependent saturable transport system is responsible for at least 94% of the measured uptake at medium myo-inositol concentrations approximating that present in plasma. This carrier-mediated transport system has a high affinity for myo-inositol (K, = 63 gtM), and is not influenced acutely by physiological concentrations of insulin; it is, however, inhibited by hyperglycemic concentrations of glucose added to the incubation medium in a primarily competitive fashion. Thus, competitive inhibition of peripheral nerve myo-inositol uptake by glucose may constitute a mechanism by which diabetes produces physiologically significant alterations in peripheral nerve myo-inositol metabolism.
nerve tissue preparation derived from rabbit sciatic nerve, whose free myo-inositol content is reduced by experimental diabetes. The results demonstrate that myo-inositol uptake occurs by at least two distinct transport systems in the normal endoneurial preparation. A sodium-and energy-dependent saturable transport system is responsible for at least 94% of the measured uptake at medium myo-inositol concentrations approximating that present in plasma. This carrier-mediated transport system has a high affinity for myo-inositol (K, = 63 gtM), and is not influenced acutely by physiological concentrations of insulin; it is, however, inhibited by hyperglycemic concentrations of glucose added to the incubation medium in a primarily competitive fashion. Thus, competitive inhibition of peripheral nerve myo-inositol uptake by glucose may constitute a mechanism by which diabetes produces physiologically significant alterations in peripheral nerve myo-inositol metabolism. INTRODUCTION Metabolic abnormalities in peripheral nerve resulting from chronic insulin deficiency and/or hyperglycemia are thought to influence heavily the development of diabetic neuropathy. Whether the major influence is mediated directly by deficient insulin action on peripheral nerve or indirectly by altered patterns of circulating metabolites is unresolved. Contrary to previous views (1, 2) , circulating insulin does not primarily regulate peripheral nerve glucose and energy metabolism (3) . Consequently, experimental diabetes does not impair glucose-derived energy production in peripheral nerve (4) although subtle insulin-sensitive metabolic perturbations in diabetic peripheral nerve have been described (4, 5) . Recent attention has focussed on possible direct pathogenetic effects of hyperglycemia on peripheral nerve metabolism (6, 7) . Both increased polyol (sorbitol) pathway activity and nonenzymatic protein-glycosylation occur in many tissues, including peripheral nerve, as a consequence of elevated ambient glucose concentration (8) (9) (10) (11) (12) (13) (14) . The relationship, however, between these metabolic abnormalities in peripheral nerve and alterations in tissue structure or function is entirely obscure (7) .
In contrast, although altered sciatic nerve myo-inositol metabolism in experimental diabetes has been explicitly linked to impairment of nerve conduction (15, 16) , the mechanism(s) by which experimental diabetes lowers nerve myo-inositol content and alters nerve myo-inositol metabolism is entirely unclear at present (17, 18) . In contrast to most other carbohydrates, myo-inositol is maintained at high intracellular concentrations by most tissues. Both endogenous synthesis from glucose and active concentration from plasma have been invoked to explain this phenomenon (19, 20) . Active concentration of myo-inositol has been described in kidney (21), small intestine (22) , choroid plexus (23) , ciliary body (24) , and ocular lens (25) . It has been postulated (17) , but never demonstrated, in peripheral nerve (20) . Although myo-inositol synthesis has been observed in crude homogenates of peripheral nerve (26) , the relative importance of active concentration, intracellular sequestration (20) , and endogenous synthesis in the maintenance of nerve myo-inositol concentrations is unknown (17, 18, 20) . In the studies presented here, we demonstrate that myo-inositol uptake occurs in endoneurial tissue via a sodiumand energy-dependent, ouabain-inhibitable, high affinity, carrier mediated transport system. Hyperglycemic concentrations of glucose competitively inhibit carrier-mediated myo-inositol uptake, and may hereby contribute to the reduction of nerve myo-inositol content in experimental diabetes.
METHODS
In vitro peripheral nerve preparations. Endoneurial preparations were derived from the tibial division of rabbit sciatic nerve as previously described (27) . Male white New Zealand rabbits weighing 1.5-2.0 kg were maintained on Wayne Rabbit Ration (free myo-inositol content, 0.04% wt/ wt) and were fasted overnight before study (fasting plasma myo-inositol concentration, 21.2±2.4 uM, n = 16). After sedation (diazepam 2 mg/kg i.m.) and induction of anesthesia (sodium pentabarbital [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] (27) .
Standard incubation medium for the endoneurial preparation was 4.5% dialyzed defatted BSA and 5 mM glucose in KRB, pH 7.4, equilibrated with 5% C02/95% 02. In contrast to previously published studies with the endoneurial preparation, myo-inositol was absent from the standard incubation medium.
In the initial characterization of the endoneurial preparation, 500,MM medium myo-inositol was necessary to prevent slow declines in oxygen uptake and tissue myo-inositol concentration (27) , but these initial studies were performed ' After brief, timed exposure to isotopically-labeled medium, the endoneurial preparation was rapidly rinsed in myo-inositol-free standard medium, and frozen in liquid nitrogen that had been evacuated to its freezing point (29) . The frozen endoneurial preparation was rapidly weighed on a microbalance, powdered in liquid nitrogen, and homogenized in 6% perchloric acid as previously described (27) . Incubation medium was quantitatively transferred to a volumetric flask and made to a 5-ml vol with water. Aliquots were deproteinized with equal volumes of 12% perchloric acid. After centrifugation at 2,500 g for 15 Laboratories, Richmond, CA) with 5 Amol of unlabeled carrier myo-inositol and mannitol and eluted to 50 ml with distilled water. The effluent was pooled, lyophilized, reconstituted in 2 ml of water, and counted in 15 ml of Aquasol II for 3H and 14C. After correction for recovery of 14C or for the recovery of pure 2-[3H]myo-inositol applied to the column, >97% of the 3H label was recovered from the column. In separate studies, the column retained >95% of myo-inositol-IP and myo-inositol-2P when eluted with 50 ml of water and assayed by the method of Barnett et al. (30) . Both phosphorylated derivatives were easily eluted by 5 N NaOH.
To assess high affinity tissue myo-inositol binding, endoneurial preparations were homogenized in 59 mM potassium phosphate buffer containing 0.3 M sucrose and 2.5 mM EDTA, and treated with charcoal (Norit A, Fisher Scientific Co., Pittsburgh, PA) as described by Peach and Russell (31 3H and "4C for determination of saturable myo-inositol uptake. The perchloric acid precipitate was extracted with calcium containing neutral and acidified chloroform methanol (32) , and the extracts were washed with appropriate upper phase (33) , pooled, evaporated under nitrogen in scintillation vials, and counted for 3H in 15 ml of Aquasol II.
Analytical methods. Tissue, diet, and plasma myo-inositol were measured by gas-liquid chromatography as previously described (15) . Tissue P-creatine was measured by an enzymatic spectrofluorometric technique (34) . Oxygen uptake was measured polarographically in a YSI Oxygen Monitor model 53 (Yellow Springs Instrument Co., Yellow Springs, OH) as previously described (27) . Reagents and standards were purchased from Sigma Chemical Co., unless otherwise stated, and were of the highest available purity.
Gas-liquid chromatographic analysis of the glucose used in these studies demonstrated no detectable myo-inositol peak. Significance of difference between groups was analyzed by the Student's two-tailed t test (35) . The differences between paired samples were analyzed by the t test for paired comparisons (35) . Kinetic (Fig. 1,  upper dotted line) . However, the differences between uptake in the presence and absence of sodium, i.e., the sodium-dependent uptake, were linear with respect to time for 15 min (Fig. 1, upper and lower dashed lines) . Therefore, 10-min incubations with 2-[3H]myo-inositol were chosen to estimate initial rates of sodium-dependent myo-inositol uptake under various incubation conditions after preincubation periods ranging from 1 to 2 h.
The mean composite (sodium-dependent plus independent) intracellular 2-[3H]myo-inositol uptake rate during 10-min incubations in the presence of sodium was measured at medium myo-inositol concentrations ranging over three orders of magnitude to detect the presence of a saturable transport component. The mean 10-min composite uptake rate increased progressively over the concentration range tested (Fig. 2,  solid (Fig. 2, dashed line) . Therefore, 2-[3H]myoinositol uptake was considered to consist of two transport components, one sodium-dependent and sat- urable, and the other sodium-independerit and unsaturable within the concentration range tested. When sodium-dependent uptake and medium myoinositol concentration were plotted as their double reciprocals (Fig. 2, inset) , or when uptake velocity was plotted as a function of the ratio of uptake velocity to medium myo-inositol concentration (Eadie-Hofstee transformation, Fig. 3, middle panel) , linear relationships were generated (r = 0.995 and 0.922, respectively). By the Lineweaver-Burk transformation of the double reciprocal plot, the apparent substrate concentration (K,) was 88.9 MM and the apparent maximum initial velocity of transport (Vmax) was 1,450 nmol/kg per min in the presence of 5 mM glucose. The EadieHofstee transformation of the Michaelis-Menten equation yielded values of 82.5 MM and 1,390 nmol/kg per min for K, and Vmax, respectively. These kinetic data suggested that sodium-dependent 2-[3H]myo-inositol uptake conformed to Michaelis-Menten kinetics, hereby implying that this uptake process represented carrier-mediated transport.
Since carrier-mediated transport systems are characteristically highly stereospecific, the ability of struc- turally similar D-glucose to inhibit sodium-dependent 2-[3H]myo-inositol uptake was assessed. When compared with uptake in physiological glucose concentrations (5 mM), sodium-dependent 2-[3H]myo-inositol uptake in 20 mM glucose was reduced by 27 and 26% at medium myo-inositol concentrations of 5 and 50 sM, respectively (Tables I and II) . Sodium-dependent myo-inositol uptake was not reduced by 20 mM glucose when medium myo-inositol concentration was 5,000 MM, i.e., >50 times the apparent K5 (Fig. 3, points nearest the vertical axis).
The Eadie-Hofstee plot of sodium-dependent 24[3H myo-inositol uptake and medium myo-inositol concentration in the presence of 20 mM glucose was linear (r = 0.921, Fig. 3, lower panel) . The apparent Vmax was 1,420 nmol/kg per min, but the apparent Kt with 20 mM glucose was 38.2% higher than at 5 mM glucose (Table III) . Sodium-dependent uptake was assessed at several concentrations of myo-inositol in the absence of glucose. Preliminary experiments demonstrated that significant decreases in tissue ATP and P-creatine were not detectable in the endoneurial preparation after 10-min incubations in the absence of substrate. The EadieHofstee plot of sodium-dependent 2-[3H]myo-inositol uptake was linear in the absence of glucose (r = 0.976, Fig. 3, upper panel) . The apparent Vrnax was 1,310 nmol/kg per min, but the apparent Kt of 63.3 ltM without glucose was lower than that at 5 or 20 m.M glucose (Table III) .
Thus, increasing medium glucose concentration was associated with progressively higher values for apparent Kt without similar increases in apparent Vmax. Dixon plots of sodium-dependent uptake at 5, 8, 16 , and 50,M myo-inositol yielded a consistent apparent Ki(glucose) of 37.8±2.2 (n = 6) (Fig. 4) . These data are consistent with the hypothesis that glucose competed with 2-[3H]myo-inositol for the transport carrier with an apparent K, of -38 mM (Table I) . However, subtle noncompetitive components to the interaction of medium glucose and 2-[3H]myo-inositol uptake cannot be rigorously excluded by the currently available data.
Sodium-dependent 2-[3H]myo-inositol uptake was washout. When endoneurial preparations were labeled in the presence of sodium at 5 MM myo-inositol, approximately one-quarter of the total tissue 3H was lost during the subsequent 10-min washout (mean A of paired samples =-28.7±3.6%, n = 6, P <0.005).
However, when tissue 3H was corrected for contaminating 2-[3H]myo-inositol remaining in the mannitol (extracellular) space, the mean A was +25.4±13.7%, n = 6, 0.2 > P > 0.1. Thus, intracellular 2-[3H]myoinositol uptake occurring primarily by the sodium-dependent system was largely irreversible (and may have continued during incubation in label-free media). In contrast, when 2-[3H]myo-inositol was introduced into the tissue in the presence of sodium at a medium myoinositol concentration of 5,000,uM, 80.1±0.9% of total and 42.7±12.2% of intracellular 3H was lost during the subsequent 10-min washout (n = 5, P < 0.001 and P <0.05, respectively). Thus, 2-[3H]myo-inositol introduced into the tissue primarily via the sodium-independent transport component equilibrated more rapidly and/or to a much greater extent with the surrounding incubation medium than did label entering the tissue by the sodium-dependent uptake component.
Sensitivity to sulfhydryl reducing agents is characteristic of some carrier-mediated transport systems, including that described for myo-inositol in choroid plexus (36) . The sensitivity of sodium-dependent endoneurial 2-[3H]myo-inositol uptake to 0.1 and 1.0 mM N-ethylmaleimide (NEM) was measured in the presence of 5 mM glucose and at myo-inositol concentrations well below and near the apparent K1 (5 and 50 MuM). In neither case did the presence of NEM alter 2-3Hlmyo-inositol uptake (Tables I and II) .
To assess energy dependence, sodium-dependent 2-[3H]myo-inositol uptake was measured in the presence of a 95% nitrogen atmosphere in medium containing 5 MM myo-inositol and 5 mM glucose. Sodium-dependent uptake was reduced by~-30% (Table II) . Tissue P-creatine concentrations were reduced by 83% from 1.54±0.15 to 0.26±0.09 mmol/kg (mean A of paired samples = -1.29±0.12 mmol/kg, n = 5, P < 0.005) during the 10-min exposure to nitrogen.
Ouabain sensitivity of sodium-dependent 2-[3H]myo- (Table I ). The resultant apparent Ki(glucose) of 37.8 mM implies an apparent affinity of the carrier for myo-inositol -500 times stronger than for glucose.
Carrier-mediated 2-[3H]myo-inositol uptake by the endoneurial preparation is tightly linked to the sodium-ion electrochemical gradient at the plasma membrane since uptake is impaired by conditions which either raise intracellular sodium (ouabain) or lower extracellular sodium (choline buffer). Metabolite-concentrating transport systems in animal cell plasma membranes uniformly depend on electrochemical gradients generated by membrane ion pumps for their energy source (39) . The sodium-gradient dependence and apparent irreversibility of carrier-mediated 2-[3H]myo-inositol uptake suggest myo-inositol concentrating capacity. (It is unlikely that nonmediated sodium-independent transport functions in this fashion since it is readily reversible). The recovery of virtually all tissue 3H in a water soluble, nonvolatile and nonpolar moiety excludes intracellular accumulation of 2-[3H]myo-inositol phosphates or phosphoinositides, or metabolism of 2-[3H]myo-inositol to myo-inosose-2 (releasing 3H20) as the basis of the irreversible carriermediated entry of 3H.
The endoneurial preparation demonstrates a stable, high tissue myo-inositol concentration, little myo-inositol efflux during incubation in myo-inositol-free medium, absence of obvious intracellular myo-inositol binding capacity, and a sodium-and energy-dependent, irreversible carrier-mediated transport system for myo-inositol. Sodium-dependent endoneurial myoinositol transport resembles saturable uptake systems in other tissues thought to concentrate myo-inositol, e.g., brain (40) , lens (25, 41) , choroid plexus (36, 42) , ciliary body (24), small intestine (22) , and kidney tubules (21, 22, 43) . Taken together, these observations suggest that carrier-mediated transport contributes to the maintenance of high myo-inositol concentrations in some endoneurial components(s). Although the transport Vmax is low, a slow-leak hypothesis has been invoked to reconcile high tissue-to-plasma myo-inositol concentration gradients with low myo-inositol transport capacity in other tissues (25) . The stability of the endoneurial intracellular myo-inositol concentration during incubation in myo-inositol-free medium is consistent with this hypothesis, i.e., the existence of a slow-leak of myo-inositol from the normal endoneurial preparation. Implicit in the slow-leak hypothesis, however, is the prediction that independent factors that influence passive efflux may prominently affect steady-state tissue-to-plasma concentration gradients.
The physiological significance of glucose-mediated inhibition of myo-inositol uptake would depend on at least two factors: (a) the quantitative contribution of sodium-dependent uptake to the maintenance of high tissue myo-inositol concentrations, and (b) the relative concentrations of glucose and myo-inositol in endoneurial fluid. Neither myo-inositol pool size nor synthetic or metabolic flux is sufficiently well characterized in peripheral nerve to permit meaningful quantitative comparison with sodium-dependent myoinositol uptake (17, 18, 26, 42, 44, 45) . Moreover, endoneurial fluid myo-inositol concentration, which may possibly differ from that of plasma (46, 47) , is unknown. However, both in vivo (48) and in vitro (3) experiments suggest that endoneurial fluid glucose freely equilibrates with plasma glucose and should therefore reflect plasma glucose concentration. Unequivocal evaluation of the physiological relevance of glucose-mediated inhibition of sodium-dependent myoinositol uptake in diabetic peripheral nerve must await reliable endoneurial fluid sampling techniques.
Furthermore, the endoneurial preparation is a composite of heterogeneous cell types, primarily myelinated and unmyelinated axons and their accompanying Schwann cells (27) . Free myo-inositol is highly and selectively concentrated within specific cell populations in brain, and a similarly heterogeneous distribution may occur in peripheral nerve (49) . Since the high tissue level of myo-inositol in peripheral nerve has been variously attributed by indirect means to both the axon (50) and the Schwann cell (38) , cellular localization of sodium-dependent myo-inositol uptake within peripheral nerve remains controversial.
The present studies describe a saturable, carriermediated sodium-and energy-dependent transport system for myo-inositol in the endoneurial preparation. Uptake by this system is not acutely influenced by physiologic concentrations of insulin, but is inhibited by hyperglycemic concentrations of glucose in a primarily competitive fashion. In view of the consistent and physiologically significant reduction in steadystate peripheral nerve myo-inositol content produced by experimental diabetes, it is reasonable to hypothesize (a) that carrier-mediated myo-inositol uptake contributes to the maintenance of high tissue myo-inositol levels within some component of peripheral nerve, and (b) that hyperglycemia reduces this concentration of free myo-inositol in part by competitively inhibiting sodium-dependent myo-inositol uptake. Thus, inhibition of peripheral nerve myo-inositol uptake by glucose constitutes a mechanism by which hyperglycemia may directly induce a specific metabolic alteration that has been implicated in impaired tissue function in experimental (15, 16) and human (51) (52) (53) diabetes.
